CepTor Corp.
Company announces new compound patents pending for Neurodur in MS
Published in Pharma Law Weekly, April 5th, 2005
More specifically, CepTor has filed to receive an additional 20 years of compound protection for oral delivery of Neurodur with accompanied use protection in multiple sclerosis (MS) and other neurodegenerative diseases.
William Pursley, CepTor's chairman and CEO, stated, "Protecting our property remains a never-ending priority. We are unaware of any other specific nerve-cell-targeted, protease-inhibiting compounds being used or developed to minimize or...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
Source: Pharma Law Weekly (2005-04-05)
More Articles from Pharma Law Weekly
- AIDS Healthcare Foundation
Legal order allows challenge to AIDS drug pricing in South African to go forward - Apogee Technology, Inc.
Testing, research initiative signed for drug delivery device - Avanir Pharmaceuticals
Rights to Neurodex technology acquired - Cleveland Clinical Foundation
Report explores ethical issues associated with patient refusal of VAD - Dartmouth Medical School
Drug therapy may be comparable to invasive cardiac procedures - Healthcare Access
Web-based program educates patients on breast, obesity surgery - More from this issue of Pharma Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
